Kexing Biopharm Co., Ltd. (SHA:688136)
China · Delayed Price · Currency is CNY 24.59
-0.61 (-2.42%)
Sep 23, 2026, 3:00 PM CST
Kexing Biopharm Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 525.62 | 650.43 | 554.56 | 568.8 | 785.38 | 877.62 |
Cash & Short-Term Investments | 609.87 | 650.43 | 554.56 | 568.8 | 785.38 | 877.62 |
Cash Growth | -1.79% | 17.29% | -2.50% | -27.58% | -10.51% | -20.41% |
Accounts Receivable | 641.69 | 727.3 | 563.82 | 342.04 | 387.44 | 382.62 |
Other Receivables | 26.74 | 29.61 | 20.61 | 6.5 | 3.25 | 2.84 |
Receivables | 668.43 | 756.92 | 584.43 | 348.54 | 390.69 | 385.46 |
Inventory | 136.19 | 139.22 | 141.81 | 191.36 | 208.18 | 172.16 |
Other Current Assets | 92.8 | 60.79 | 7.01 | 24.93 | 27.06 | 25.57 |
Total Current Assets | 1,507 | 1,607 | 1,288 | 1,134 | 1,411 | 1,461 |
Property, Plant & Equipment | 1,087 | 1,099 | 1,177 | 1,200 | 1,053 | 936.24 |
Long-Term Investments | 556.73 | 311.58 | 203.41 | 245.32 | 15 | 247.46 |
Other Intangible Assets | 215.8 | 229.48 | 225.14 | 158.72 | 165.82 | 26.96 |
Long-Term Accounts Receivable | - | - | - | - | 0.31 | - |
Long-Term Deferred Tax Assets | 147.29 | 120.71 | 117.22 | 133.98 | 80.83 | 12.1 |
Long-Term Deferred Charges | 127.27 | 101.15 | 50.37 | 3.08 | - | 21.82 |
Other Long-Term Assets | 70.3 | 64.17 | 101.02 | 156.61 | 438.91 | 123.64 |
Total Assets | 3,712 | 3,534 | 3,162 | 3,031 | 3,165 | 2,829 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 85.37 | 75.98 | 71.91 | 56.02 | 67.78 | 65.73 |
Accrued Expenses | 157.93 | 163.73 | 112.38 | 84.14 | 92.89 | 97.63 |
Short-Term Debt | 225.01 | 162.83 | 269.12 | 120.7 | 162.69 | 276.26 |
Current Portion of Long-Term Debt | 543.23 | 500.34 | 313.25 | 275.03 | 51.78 | - |
Current Portion of Leases | 10.13 | 4.07 | 12.45 | 6.7 | 19.87 | 18.39 |
Current Income Taxes Payable | 4.06 | 0.8 | 0.6 | - | - | - |
Current Unearned Revenue | 17.15 | 13.53 | 9.78 | 20.44 | 17.99 | 7.16 |
Other Current Liabilities | 78.15 | 99.99 | 96.91 | 106.97 | 126.36 | 138.44 |
Total Current Liabilities | 1,121 | 1,021 | 886.4 | 669.99 | 539.37 | 603.61 |
Long-Term Debt | 675.04 | 727.7 | 611.18 | 695.84 | 779.23 | 263.37 |
Long-Term Leases | 5.8 | 1.82 | 14.78 | 17.79 | 24.96 | 43.25 |
Long-Term Unearned Revenue | 15.45 | 11.28 | 3.15 | 5.32 | 0.75 | 0.99 |
Long-Term Deferred Tax Liabilities | 56.91 | 18.99 | 7.48 | 11.36 | 14.55 | 7.12 |
Total Liabilities | 1,874 | 1,781 | 1,523 | 1,400 | 1,359 | 918.34 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 201.99 | 201.26 | 199.64 | 199.2 | 198.7 | 198.7 |
Additional Paid-In Capital | 1,320 | 1,313 | 1,288 | 1,282 | 1,274 | 1,266 |
Retained Earnings | 401.05 | 316.57 | 176.78 | 145.3 | 335.59 | 445.76 |
Treasury Stock | -86.18 | -80.36 | -31.12 | - | - | - |
Comprehensive Income & Other | 0.7 | 0.93 | 1.11 | -0.01 | - | - |
Total Common Equity | 1,838 | 1,751 | 1,635 | 1,626 | 1,808 | 1,911 |
Minority Interest | 0.05 | 1.51 | 4.34 | 4.77 | -2.53 | - |
Shareholders' Equity | 1,838 | 1,753 | 1,639 | 1,631 | 1,806 | 1,911 |
Total Liabilities & Equity | 3,712 | 3,534 | 3,162 | 3,031 | 3,165 | 2,829 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 1,459 | 1,397 | 1,221 | 1,116 | 1,039 | 601.27 |
Net Cash (Debt) | -849.34 | -746.33 | -666.22 | -547.26 | -253.16 | 276.35 |
Net Cash Growth | - | - | - | - | - | -64.88% |
Net Cash Per Share | -4.30 | -3.79 | -3.39 | -2.76 | -1.26 | 1.40 |
Filing Date Shares Outstanding | 198.59 | 198.06 | 197.76 | 199.2 | 198.7 | 198.7 |
Total Common Shares Outstanding | 198.59 | 198.06 | 197.76 | 199.2 | 198.7 | 198.7 |
Working Capital | 386.25 | 586.1 | 401.41 | 463.63 | 871.94 | 857.2 |
Book Value Per Share | 9.25 | 8.84 | 8.27 | 8.16 | 9.10 | 9.62 |
Tangible Book Value | 1,622 | 1,522 | 1,410 | 1,467 | 1,643 | 1,884 |
Tangible Book Value Per Share | 8.17 | 7.68 | 7.13 | 7.37 | 8.27 | 9.48 |
Buildings | 779.12 | 778.16 | 754.25 | 662.95 | 609.2 | 361.78 |
Machinery | 562.94 | 554.67 | 514.22 | 370.42 | 326.3 | 243.82 |
Construction In Progress | 113.94 | 110.61 | 176.82 | 372.56 | 256.57 | 428.52 |